



August 3, 2021

To: Directors of Clinical Laboratories
Directors of Transfusion Services

Subject: **Pooled Pathogen Reduced Cryoprecipitate**

LifeSouth is pleased to introduce two new components, Pathogen Reduced Cryoprecipitated Fibrinogen Complex (PRCFC) and Pathogen Reduced Plasma, Cryoprecipitate Reduced (PRPCR), which provide “broad spectrum” transfusion-transmitted infection risk reduction.

Pathogen Reduced Cryoprecipitated Fibrinogen Complex (PRCFC)

PRCFC has a one-year frozen shelf life at -18°C or colder, a 5-day post-thaw shelf life at room temperature, and does not require a laboratory test result prior to administration. These factors allow you to maintain an inventory of thawed PRCFC, allowing immediate availability of cryoprecipitate fibrinogen complex for specified patients. Due to the 5-day post-thaw shelf life, wastage will be minimized as compared to the use of conventional cryoprecipitate. PRCFC is indicated for the following:

- Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
- Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available.
- Second-line therapy for von Willebrand disease (vWD).
- Control of uremic bleeding after other treatment modalities have failed.

PRCFC should not be used for treatment of congenital factor VIII deficiency.

Pathogen Reduced Plasma, Cryoprecipitate Reduced (PRPCR)

PRPCR has a one-year frozen shelf life at -18°C or colder, a 5-day post-thaw shelf life and is indicated for transfusion or therapeutic plasma exchange (TPE) in patients with thrombotic thrombocytopenic purpura (TTP). Pathogen reduced cryoprecipitate-poor plasma offers the potential to reduce the risk of transfusion-transmitted infections in TTP patients treated with TPE and contains less clot-forming proteins than plasma. This product does not provide the following coagulation factors: fibrinogen, factor VIII, factor XIII, and von Willebrand factor (vWF), and should not be used to support patients that are in need of these coagulation factors.

Product Codes

The following table includes the ISBT component codes currently assigned to pathogen reduced cryoprecipitated products. Your computer system should be able to accept all these new products.

Code	ISBT 128 Description
EA484	Apheresis FIBRINOGEN COMPLEX None/XX/<=-18C Cryoprecipitated Psoralen-treated
EA485	Apheresis POOLED FIBRINOGEN COMPLEX None/XX/<=-18C Cryoprecipitated Psoralen-treated From 2 donors
EA486	Apheresis POOLED FIBRINOGEN COMPLEX None/XX/<=-18C Cryoprecipitated Psoralen-treated From 3 donors
EA487	Apheresis POOLED FIBRINOGEN COMPLEX None/XX/<=-18C Cryoprecipitated Psoralen-treated From 4 donors
EA488	Apheresis POOLED FIBRINOGEN COMPLEX None/XX/<=-18C Cryoprecipitated Psoralen-treated From 5 donors
EA489	POOLED FIBRINOGEN COMPLEX None/XX/<=-18C Cryoprecipitated Psoralen-treated From 2 donors

EA490	POOLED FIBRINOGEN COMPLEX None/XX/<=-18C Cryoprecipitated Psoralen-treated From 4 donors
EA491	POOLED FIBRINOGEN COMPLEX None/XX/<=-18C Cryoprecipitated Psoralen-treated From 6 donors
EA492	POOLED FIBRINOGEN COMPLEX None/XX/<=-18C Cryoprecipitated Psoralen-treated From 8 donors
EA493	POOLED FIBRINOGEN COMPLEX None/XX/<=-18C Cryoprecipitated Psoralen-treated From 10 donors
EA504	Apheresis PLASMA ACD-A/XX/<=-18C Cryo reduced Psoralen-treated
EA510	POOLED PLASMA CPD/XX/<=-18C Cryo reduced Psoralen-treated From 2 donors
EA512	POOLED PLASMA CP2D/XX/<=-18C Cryo reduced Psoralen-treated From 2 donors

For technical questions, contact Dr. Chris Lough, Vice President of Medical Services, at 352-224-1644. For product availability, contact JD Pettyjohn, Chief Operating Officer, at 352-224-1705.